Speaker: Jens Juul Holst, Professor, University of Copenhagen Date & Time : October 25, 15:00 - 16:00 Helix Lab is open for coffee and networking from 14:00-17:00 Helix Lab is funded by the Novo Nordisk Foundation, Novo Nordisk A/S, and Novozymes A/S.
Both companies have built extensive patent thickets around their core molecules, with Novo Nordisk in particular pursuing aggressive filing strategies across new formulations, indications, and delivery methods
Ro reaches out to the prospective patients insurance company and shares a free report that includes recommended paths based on estimated copay and medication supply. The cost breakdown: Program costs vary, but the Body Program, which includes prescriptions for weight loss drugs but not the medications themselves costs $45 for the first month and $145 for each month beyond that
Retatrutide is a triple-receptor agonist targeting GIP, GLP-1, and glucagon receptors
Hyperglycemia induces NF-kappaB activation and MCP-1 expression via downregulating GLP-1R expression in rat mesangial cells: inhibition by metformin
Phase 3 trials are ongoing with projected approval timelines between late 2026 and early 2027